Glenmark Pharmaceuticals has posted a consolidated revenue of Rs 1463 crore for the second quarter ended September 30, 2013, an increase of 16.56% compared with Rs 1255.19 crore in Q2 2012-13. Revenue from the generics business was at Rs 710.655 crore in Q2FY14 as against Rs 580.078 crore in Q2FY13, growth of 22.51%. The specialty formulation business excluding out-licensing revenue was at Rs 740.541 crore as against Rs 675.113 crore for the corresponding previous quarter, recording a growth of 9.69%. But, Glenmark’s net profit (after taxes and minority interests) for the second quarter was Rs 154.297 crore down 1.5% compared to Rs 156.752 crore for the previous corresponding quarter.
ALSO READ: Jubilant Life Sciences consolidates pharma business under its Signapore subsidiary
Glenn Saldanha, Chairman and MD, Glenmark, commented, “Despite challenges in the operating environment, we have managed to register decent sales growth of 17% on the back of good performances by our US and India businesses. We have been also making steady progress on the Innovation R&D front with our 4 NCE & NBE molecules in clinical trials. Although the operating environment continues to remain challenging in emerging markets, we are reasonably confident of continuing on the same growth trajectory.”
ALSO READ: Jubilant Life Sciences consolidates pharma business under its Signapore subsidiary
Glenn Saldanha, Chairman and MD, Glenmark, commented, “Despite challenges in the operating environment, we have managed to register decent sales growth of 17% on the back of good performances by our US and India businesses. We have been also making steady progress on the Innovation R&D front with our 4 NCE & NBE molecules in clinical trials. Although the operating environment continues to remain challenging in emerging markets, we are reasonably confident of continuing on the same growth trajectory.”